The pathogenesis of mixed-lineage leukemia

Annual Review of Pathology: Mechanisms of Disease

Volumn 7, Issue , 2012, Pages 283-301

  Muntean, Andrew G ^a   Hess, Jay L ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Epigenetics; Histone methylation; Therapeutics; Transcription; Translocation

Indexed keywords

HYBRID PROTEIN; MIXED LINEAGE LEUKEMIA PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; CHROMOSOME 11Q; CHROMOSOME 4; CHROMOSOME REARRANGEMENT; CHROMOSOME TRANSLOCATION; CLINICAL FEATURE; CYTOGENETICS; DIMERIZATION; GENE AMPLIFICATION; GENE LOCUS; GENE TARGETING; HUMAN; LEUKEMIA; MIXED LINEAGE LEUKEMIA; MOLECULAR BIOLOGY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW;

GENES, HOMEOBOX; HISTONE-LYSINE N-METHYLTRANSFERASE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MYELODYSPLASTIC SYNDROMES; MYELOID-LYMPHOID LEUKEMIA PROTEIN; ONCOGENE PROTEINS, FUSION; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; TRANSLOCATION, GENETIC;

EID: 84856916060     PISSN: 15534006     EISSN: 15534014     Source Type: Book Series    
DOI: 10.1146/annurev-pathol-011811-132434     Document Type: Review

References (116)

1. Djabali M, Selleri L, Parry P, BowerM, Young BD, Evans GA. 1992. A trithorax-like gene is interrupted by chromosome 11q23 translocations in acute leukaemias. Nat. Genet. 2:113-18
2. Gu Y, Nakamura T, Alder H, Prasad R, Canaani O, et al. 1992. The t(4;11) chromosome translocation of human acute leukemias fuses the ALL-1 gene, related to Drosophila trithorax, to the AF-4 gene. Cell 71:701-8
3. Tkachuk DC, Kohler S, Cleary ML. 1992. Involvement of a homolog of Drosophila trithorax by 11q23 chromosomal translocations in acute leukemias. Cell 71:691-700
4. Krivtsov AV, Armstrong SA. 2007. MLL translocations, histone modifications and leukaemia stem-cell development. Nat. Rev. Cancer 7:823-33 (Pubitemid 350006257)
5. Hess JL. 2004. MLL: a histone methyltransferase disrupted in leukemia. Trends Mol. Med. 10:500-7 (Pubitemid 39303623)
6. Meyer C, Kowarz E, Hofmann J, Renneville A, Zuna J, et al. 2009. New insights to the MLL recombinome of acute leukemias. Leukemia 23:1490-99
7. Huret JL, Dessen P, Le Minor S, Bernheim A. 2000. The "Atlas of Genetics and Cytogenetics in Oncology and Haematology" on the internet and a review on infant leukemias. Cancer Genet. Cytogenet. 120:155-59 (Pubitemid 30609696)
8. Raimondi S. 2004. 11q23 rearrangements in childhood acute lymphoblastic leukemia. Atlas Genet. Cytogenet. Oncol. Haematol. http://atlasgeneticsoncology. org/Anomalies/ 11q23ChildALLID1321.html
9. MohanM, Lin C, Guest E, Shilatifard A. 2010. Licensed to elongate: a molecular mechanism for MLLbased leukaemogenesis. Nat. Rev. Cancer 10:721-28
10. Huret JL. 1997. t(9;11)(p22;q23). AtlasGenet. Cytogenet.Oncol.Haematol. http://atlasgeneticsoncology.org/Anomalies/t0911.html
11. Huret JL. 2003. 11q23 rearrangements in leukaemia. Atlas Genet. Cytogenet. Oncol. Haematol. http://atlasgeneticsoncology.org/Anomalies/ 11q23ID1030.html
12. Ringrose L, Paro R. 2004. Epigenetic regulation of cellular memory by the Polycomb and trithorax group proteins. Annu. Rev. Genet. 38:413-43 (Pubitemid 40013734)
13. Brock HW, van Lohuizen M. 2001. The Polycomb group-no longer an exclusive club? Curr. Opin. Genet. Dev. 11:175-81 (Pubitemid 32209202)
14. Argiropoulos B, Humphries RK. 2007. Hox genes in hematopoiesis and leukemogenesis. Oncogene 26:6766-76 (Pubitemid 47585101)
15. Bernstein BE, Mikkelsen TS, Xie X, Kamal M, Huebert DJ, et al. 2006. A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell 125:315-26
16. Chopra VS, Hong JW, Levine M. 2009. Regulation of Hox gene activity by transcriptional elongation in Drosophila. Curr. Biol. 19:688-93
17. Muse GW, Gilchrist DA, Nechaev S, Shah R, Parker JS, et al. 2007. RNA polymerase is poised for activation across the genome. Nat. Genet. 39:1507-11 (Pubitemid 350191341)
18. Milne TA, Briggs SD, Brock HW, Martin ME, Gibbs D, et al. 2002. MLL targets SET domain methyltransferase activity to Hox gene promoters. Mol. Cell 10:1107-17 (Pubitemid 35453828)
19. Nakamura T, Mori T, Tada S, Krajewski W, Rozovskaia T, et al. 2002. ALL-1 is a histone methyltransferase that assembles a supercomplex of proteins involved in transcriptional regulation. Mol. Cell 10:1119-28 (Pubitemid 35453829)
20. Yu BD, Hanson RD, Hess JL, Horning SE, Korsmeyer SJ. 1998. MLL, a mammalian trithorax-group gene, functions as a transcriptional maintenance factor in morphogenesis. Proc. Natl. Acad. Sci. USA 95:10632-36 (Pubitemid 28413119)
21. Yu BD, Hess JL, Horning SE, Brown GA, Korsmeyer SJ. 1995. Altered Hox expression and segmental identity in Mll-mutant mice. Nature 378:505-8
22. Hess JL, Yu BD, Li B, Hanson R, Korsmeyer SJ. 1997. Defects in yolk sac hematopoiesis in Mll-null embryos. Blood 90:1799-806 (Pubitemid 27377289)
23. Jude CD, Climer L, Xu D, Artinger E, Fisher JK, Ernst P. 2007. Unique and independent roles for MLL in adult hematopoietic stem cells and progenitors. Cell Stem Cell 1:324-37 (Pubitemid 47355322)
24. McMahon KA, Hiew SY, Hadjur S, Veiga-Fernandes H, Menzel U, et al. 2007. Mll has a critical role in fetal and adult hematopoietic stem cell self-renewal. Cell Stem Cell 1:338-45 (Pubitemid 47355325)
25. Hsieh JJ, Ernst P, Erdjument-Bromage H, Tempst P, Korsmeyer SJ. 2003. Proteolytic cleavage of MLL generates a complex of N- and C-terminal fragments that confers protein stability and subnuclear localization. Mol. Cell. Biol. 23:186-94 (Pubitemid 36008512)
26. Hsieh JJ, Cheng EH, Korsmeyer SJ. 2003. Taspase1: a threonine aspartase required for cleavage of MLL and proper HOX gene expression. Cell 115:293-303 (Pubitemid 37487703)
27. Takeda S, Chen DY, Westergard TD, Fisher JK, Rubens JA, et al. 2006. Proteolysis of MLL family proteins is essential for Taspase1-orchestrated cell cycle progression. Genes Dev. 20:2397-409 (Pubitemid 44320388)
28. Allen MD, Grummitt CG, Hilcenko C, Min SY, Tonkin LM, et al. 2006. Solution structure of the nonmethyl-CpG-binding CXXC domain of the leukaemia-associated MLL histone methyltransferase. EMBO J. 25:4503-12 (Pubitemid 44498124)
29. Birke M, Schreiner S, Garcia-Cuellar MP, Mahr K, Titgemeyer F, Slany RK. 2002. The MT domain of the proto-oncoprotein MLL binds to CpG-containing DNA and discriminates against methylation. Nucleic Acids Res. 30:958-65 (Pubitemid 34679664)
30. Cierpicki T, Risner LE, Grembecka J, Lukasik SM, Popovic R, et al. 2009. Structure of the MLL CXXC domain-DNA complex and its functional role in MLL-AF9 leukemia. Nat. Struct. Mol. Biol. 17:62-68
31. Erfurth FE, Popovic R, Grembecka J, Cierpicki T, Theisler C, et al. 2008. MLL protects CpG clusters from methylation within the Hoxa9 gene, maintaining transcript expression. Proc. Natl. Acad. Sci. USA 105:7517-22 (Pubitemid 351830050)
32. Zeleznik-Le NJ, Harden AM, Rowley JD. 1994. 11q23 translocations split the "AT-hook" cruciform DNA-binding region and the transcriptional repression domain from the activation domain of themixedlineage leukemia (MLL) gene. Proc. Natl. Acad. Sci. USA 91:10610-14
33. Chang PY, Hom RA, Musselman CA, Zhu L, Kuo A, et al. 2010. Binding of the MLL PHD3 finger to histone H3K4me3 is required for MLL-dependent gene transcription. J. Mol. Biol. 400:137-44
34. Milne TA, Kim J, Wang GG, Stadler SC, Basrur V, et al. 2010. Multiple interactions recruitMLL1 and MLL1 fusion proteins to the HOXA9 locus in leukemogenesis. Mol. Cell 38:853-63
35. Wang Z, Song J, Milne TA, Wang GG, Li H, et al. 2010. Pro isomerization in MLL1 PHD3-bromo cassette connects H3K4me readout to CyP33 and HDAC-mediated repression. Cell 141:1183-94
36. Ernst P, Wang J, Huang M, Goodman RH, Korsmeyer SJ. 2001. MLL and CREB bind cooperatively to the nuclear coactivator CREB-binding protein. Mol. Cell. Biol. 21:2249-58 (Pubitemid 32222079)
37. Steward MM, Lee JS, O'Donovan A, Wyatt M, Bernstein BE, Shilatifard A. 2006. Molecular regulation of H3K4 trimethylation by ASH2L, a shared subunit ofMLLcomplexes. Nat. Struct. Mol. Biol. 13:852-54 (Pubitemid 44338781)
38. Wysocka J, Swigut T, Milne TA, Dou Y, Zhang X, et al. 2005. WDR5 associates with histone H3 methylated at K4 and is essential for H3 K4 methylation and vertebrate development. Cell 121:859-72 (Pubitemid 40806418)
39. Dou Y, Milne TA, Ruthenburg AJ, Lee S, Lee JW, et al. 2006. Regulation ofMLL1 H3K4 methyltransferase activity by its core components. Nat. Struct. Mol. Biol. 13:713-19 (Pubitemid 44175164)
40. Dou Y, Milne TA, Tackett AJ, Smith ER, Fukuda A, et al. 2005. Physical association and coordinate function of theH3K4methyltransferase MLL1and the H4 K16 acetyltransferaseMOF. Cell 121:873-85 (Pubitemid 40806419)
41. Xia ZB, Anderson M, Diaz MO, Zeleznik-Le NJ. 2003. MLL repression domain interacts with histone deacetylases, the polycomb group proteins HPC2 and BMI-1, and the corepressor C-terminal-binding protein. Proc. Natl. Acad. Sci. USA 100:8342-47 (Pubitemid 36842547)
42. Yokoyama A, Wang Z, Wysocka J, Sanyal M, Aufiero DJ, et al. 2004. Leukemia proto-oncoprotein MLLforms a SET1-like histone methyltransferase complex with Menin to regulate Hox gene expression. Mol. Cell. Biol. 24:5639-49 (Pubitemid 38787950)
43. Tyagi S, Chabes AL, Wysocka J, Herr W. 2007. E2F activation of S phase promoters via association with HCF-1 and the MLL family of histone H3K4 methyltransferases. Mol. Cell 27:107-19 (Pubitemid 46991384)
44. Caslini C, Yang Z, El-Osta M, Milne TA, Slany RK, Hess JL. 2007. Interaction ofMLL amino terminal sequences with Menin is required for transformation. Cancer Res. 67:7275-83 (Pubitemid 47206556)
45. Yokoyama A, Somervaille TC, Smith KS, Rozenblatt-Rosen O, Meyerson M, Cleary ML. 2005. The Menin tumor suppressor protein is an essential oncogenic cofactor forMLL-associated leukemogenesis. Cell 123:207-18 (Pubitemid 41457212)
46. Grembecka J, Belcher AM, Hartley T, Cierpicki T. 2010. Molecular basis of the mixed lineage leukemia- Menin interaction: implications for targeting mixed lineage leukemias. J. Biol. Chem. 285:40690-98
47. Yokoyama A, Cleary ML. 2008. Menin critically links MLL proteins with LEDGF on cancer-associated target genes. Cancer Cell 14:36-46 (Pubitemid 351885493)
48. Muntean AG, Tan J, Sitwala K, Huang Y, Bronstein J, et al. 2010. The PAF complex synergizes with MLL fusion proteins at HOX loci to promote leukemogenesis. Cancer Cell 17:609-21
49. Dover J, Schneider J, Tawiah-Boateng MA, Wood A, Dean K, et al. 2002. Methylation of histone H3 by COMPASS requires ubiquitination of histone H2B by Rad6. J. Biol. Chem. 277:28368-71 (Pubitemid 41079257)
50. KroganNJ, Dover J, Wood A, Schneider J, Heidt J, et al. 2003. The Paf1 complex is required for histone H3 methylation by COMPASS and Dot1p: linking transcriptional elongation to histone methylation. Mol. Cell 11:721-29 (Pubitemid 36385125)
51. Ng HH, Dole S, Struhl K. 2003. The Rtf1 component of the Paf1 transcriptional elongation complex is required for ubiquitination of histone H2B. J. Biol. Chem. 278:33625-28 (Pubitemid 37553194)
52. Sun ZW, Allis CD. 2002. Ubiquitination of histone H2B regulates H3 methylation and gene silencing in yeast. Nature 418:104-8 (Pubitemid 34742580)
53. Milne TA, Martin ME, Brock HW, Slany RK, Hess JL. 2005. LeukemogenicMLL fusion proteins bind across a broad region of the Hox a9 locus, promoting transcription and multiple histone modifications. Cancer Res. 65:11367-74 (Pubitemid 41821694)
54. Arai S, Yoshimi A, Shimabe M, Ichikawa M, Nakagawa M, et al. 2010. Evi-1 is a transcriptional target of mixed-lineage leukemia oncoproteins in hematopoietic stem cells. Blood 117:6304-14
55. Milne TA, Hughes CM, Lloyd R, Yang Z, Rozenblatt-Rosen O, et al. 2005. Menin and MLL cooperatively regulate expression of cyclin-dependent kinase inhibitors. Proc. Natl. Acad. Sci. USA 102:749-54 (Pubitemid 40282737)
56. Xia ZB, Popovic R, Chen J, Theisler C, Stuart T, et al. 2005. TheMLL fusion gene, MLL-AF4, regulates cyclin-dependent kinase inhibitor CDKN1B (p27kip1) expression. Proc. Natl. Acad. Sci. USA 102:14028-33 (Pubitemid 41377697)
57. Liu H, Cheng EH, Hsieh JJ. 2007. Bimodal degradation of MLL by SCFSkp2 and APCCdc20 assures cell cycle execution: a critical regulatory circuit lost in leukemogenic MLL fusions. Genes Dev. 21:2385-98 (Pubitemid 47529369)
58. Dobson CL, Warren AJ, Pannell R, Forster A, Rabbitts TH. 2000. Tumorigenesis in mice with a fusion of the leukaemia oncogene Mll and the bacterial lacZ gene. EMBO J. 19:843-51 (Pubitemid 30119810)
59. Liu H, Takeda S, Kumar R, Westergard TD, Brown EJ, et al. 2010. Phosphorylation of MLL by ATR is required for execution of mammalian S-phase checkpoint. Nature 467:343-46
60. Caslini C, Connelly JA, Serna A, Broccoli D, Hess JL. 2009.MLLassociates with telomeres and regulates telomeric repeat-containing RNA transcription. Mol. Cell. Biol. 29:4519-26
61. Gessner A, Thomas M, Castro PG, Buchler L, Scholz A, et al. 2010. Leukemic fusion genes MLL/AF4 and AML1/MTG8 support leukemic self-renewal by controlling expression of the telomerase subunit TERT. Leukemia 24:1751-59
62. Martin ME, Milne TA, Bloyer S, Galoian K, Shen W, et al. 2003. Dimerization ofMLL fusion proteins immortalizes hematopoietic cells. Cancer Cell 4:197-207 (Pubitemid 37163834)
63. Zeisig BB, Milne T, Garcia-Cuellar MP, Schreiner S, Martin ME, et al. 2004. Hoxa9 and Meis1 are key targets for MLL-ENL-mediated cellular immortalization. Mol. Cell. Biol. 24:617-28 (Pubitemid 38057914)
64. Nakamura T, Largaespada DA, Shaughnessy JD Jr, Jenkins NA, Copeland NG. 1996. Cooperative activation of Hoxa and Pbx1-related genes in murine myeloid leukaemias. Nat. Genet. 12:149-53 (Pubitemid 26051294)
65. Moskow JJ, Bullrich F, Huebner K, Daar IO, Buchberg AM. 1995. Meis1, a PBX1-related homeobox gene involved in myeloid leukemia in BXH-2 mice. Mol. Cell. Biol. 15:5434-43
66. Rozovskaia T, Feinstein E, Mor O, Foa R, Blechman J, et al. 2001. Upregulation of Meis1 and HoxA9 in acute lymphocytic leukemias with the t(4:11) abnormality. Oncogene 20:874-78 (Pubitemid 32198181)
67. Ferrando AA, Armstrong SA, Neuberg DS, Sallan SE, Silverman LB, et al. 2003. Gene expression signatures inMLL-rearranged T-lineage andB-precursor acute leukemias: dominance of HOXdysregulation. Blood 102:262-68 (Pubitemid 36759663)
68. Casas S, Nagy B, Elonen E, Aventin A, Larramendy ML, et al. 2003. Aberrant expression of HOXA9, DEK, CBL and CSF1R in acute myeloid leukemia. Leuk. Lymphoma 44:1935-41 (Pubitemid 37369627)
69. Armstrong SA, Staunton JE, Silverman LB, Pieters R, den Boer ML, et al. 2002. MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat. Genet. 30:41-47
70. Stam RW, Schneider P, Hagelstein JA, van der Linden MH, Stumpel DJ, et al. 2010. Gene expression profiling-based dissection of MLL translocated and MLL germline acute lymphoblastic leukemia in infants. Blood 115:2835-44
71. AytonPM, ClearyML.2003. Transformation of myeloid progenitors byMLLoncoproteins is dependent on Hoxa7 and Hoxa9. Genes Dev. 17:2298-307 (Pubitemid 37128644)
72. Avet-Loiseau H, Godon C, Li JY, Daviet A, MellerinMP, et al. 1999. Amplification of the 11q23 region in acute myeloid leukemia. Genes Chromosomes Cancer 26:166-70 (Pubitemid 29416442)
73. Reddy KS, Parsons L, Mak L, Dighe P, Saphner T, et al. 2001. Segmental amplification of 11q23 region identified by fluorescence in situ hybridization in four patients with myeloid disorders: a review. Cancer Genet. Cytogenet. 126:139-46 (Pubitemid 32453331)
74. Poppe B, Vandesompele J, Schoch C, Lindvall C, Mrozek K, et al. 2004. Expression analyses identify MLLas a prominent target of 11q23 amplification and support an etiologic role forMLLgain of function in myeloid malignancies. Blood 103:229-35 (Pubitemid 38029943)
75. Kroon E, Krosl J, Thorsteinsdottir U, Baban S, Buchberg AM, Sauvageau G. 1998. Hoxa9 transforms primary bonemarrow cells through specific collaboration with Meis1a but not Pbx1b. EMBO J. 17:3714-25 (Pubitemid 28327389)
76. Popovic R, Riesbeck LE, Velu CS, Chaubey A, Zhang J, et al. 2009. Regulation of miR-196b by MLL and its overexpression by MLL fusions contributes to immortalization. Blood 113:3314-22
77. Somervaille TC, Matheny CJ, Spencer GJ, Iwasaki M, Rinn JL, et al. 2009. Hierarchical maintenance of MLL myeloid leukemia stem cells employs a transcriptional program shared with embryonic rather than adult stem cells. Cell Stem Cell 4:129-40
78. Wang Y, Krivtsov AV, Sinha AU, NorthTE, GoesslingW, et al. TheWnt/α-catenin pathway is required for the development of leukemia stem cells in AML. Science 327:1650-53
79. Muntean AG, Giannola D, Udager AM, Hess JL. 2008. The PHD fingers of MLL block MLL fusion protein-mediated transformation. Blood 112:4690-93
80. Bitoun E, Oliver PL, Davies KE. 2007. The mixed-lineage leukemia fusion partner AF4 stimulates RNA polymerase II transcriptional elongation and mediates coordinated chromatin remodeling. Hum. Mol. Genet. 16:92-106 (Pubitemid 46152547)
81. Monroe SC, Jo SY, Sanders DS, Basrur V, Elenitoba-Johnson KS, et al. 2011. MLL-AF9 and MLLENL alter the dynamic association of transcriptional regulators with genes critical for leukemia. Exp. Hematol. 39:77-86
82. Lin C, Smith ER, Takahashi H, Lai KC, Martin-Brown S, et al. 2010. AFF4, a component of the ELL/PTEFb elongation complex and a shared subunit of MLL chimeras, can link transcription elongation to leukemia. Mol. Cell 37:429-37
83. Mueller D, Garcia-Cuellar MP, Bach C, Buhl S, Maethner E, Slany RK. 2009. Misguided transcriptional elongation causes mixed lineage leukemia. PLoS Biol. 7:e1000249
84. Mohan M, Herz HM, Takahashi YH, Lin C, Lai KC, et al. 2010. Linking H3K79 trimethylation to Wnt signaling through a novel Dot1-containing complex (DotCom). Genes Dev. 24:574-89
85. Yokoyama A, Lin M, Naresh A, Kitabayashi I, Cleary ML. 2010. A higher-order complex containing AF4 and ENL family proteins with P-TEFb facilitates oncogenic and physiologic MLL-dependent transcription. Cancer Cell 17:198-212
86. Zeisig DT, Bittner CB, Zeisig BB, Garcia-Cuellar MP, Hess JL, Slany RK. 2005. The eleven-nineteenleukemia protein ENL connects nuclear MLL fusion partners with chromatin. Oncogene 24:5525-32 (Pubitemid 43080096)
87. Slany RK, Lavau C, Cleary ML. 1998. The oncogenic capacity ofHRX-ENL requires the transcriptional transactivation activity of ENL and the DNA binding motifs of HRX. Mol. Cell. Biol. 18:122-29 (Pubitemid 28021024)
88. Shilatifard A, LaneWS, Jackson KW, Conaway RC, Conaway JW. 1996. An RNA polymerase II elongation factor encoded by the human ELL gene. Science 271:1873-76 (Pubitemid 26112315)
89. Okada Y, Feng Q, Lin Y, Jiang Q, Li Y, et al. 2005. hDOT1L links histone methylation to leukemogenesis. Cell 121:167-78 (Pubitemid 40546386)
90. Jo SY, Granowicz EM, Maillard I, Thomas D, Hess JL. 2011. Requirement forDot1l in murine postnatal hematopoiesis and leukemogenesis by MLL translocation. Blood 117:4759-68
91. Chang MJ, Wu H, Achille NJ, Reisenauer MR, Chou CW, et al. 2010. Histone H3 lysine 79 methyltransferase Dot1 is required for immortalization by MLL oncogenes. Cancer Res. 70:10234-42
92. Lavau C, Du C, Thirman M, Zeleznik-LeN. 2000. Chromatin-related properties of CBP fused toMLL generate a myelodysplastic-like syndrome that evolves into myeloid leukemia. EMBO J. 19:4655-64
93. Cheung N, Chan LC, Thompson A, Cleary ML, So CW. 2007. Protein arginine-methyltransferasedependent oncogenesis. Nat. Cell Biol. 9:1208-15
94. Thiel AT, Blessington P, Zou T, Feather D, Wu X, et al. 2010. MLL-AF9-induced leukemogenesis requires coexpression of the wild-type Mll allele. Cancer Cell 17:148-59
95. Bursen A, Schwabe K, Ruster B, Henschler R, Ruthardt M, et al. The AF4.MLL fusion protein is capable of inducing ALL in mice without requirement of MLL.AF4. Blood 115:3570-79
96. Benedikt A, Baltruschat S, Scholz B, Bursen A, Arrey TN, et al. 2011. The leukemogenic AF4-MLL fusion protein causes P-TEFb kinase activation and altered epigenetic signatures. Leukemia 25:135-44
97. So CW, Lin M, Ayton PM, Chen EH, Cleary ML. 2003. Dimerization contributes to oncogenic activation of MLL chimeras in acute leukemias. Cancer Cell 4:99-110 (Pubitemid 37040826)
98. Ono R, Nakajima H, Ozaki K, Kumagai H, Kawashima T, et al. 2005. Dimerization of MLL fusion proteins and FLT3 activation synergize to induce multiple-lineage leukemogenesis. J. Clin. Investig. 115:919-29 (Pubitemid 40489396)
99. Herry A, Douet-Guilbert N, Gueganic N, Morel F, Le Bris MJ, et al. 2006. Del(5q) and MLL amplification in homogeneously staining region in acute myeloblastic leukemia: a recurrent cytogenetic association. Ann. Hematol. 85:244-49
100. Worrell RT, Oghene J, Matthews JB. 2004. Ammonium effects on colonic Cl secretion: anomalous mole fraction behavior. Am. J. Physiol. Gastrointest. Liver Physiol. 286:14-22
101. Basecke J, Whelan JT, Griesinger F, Bertrand FE. 2006. The MLL partial tandem duplication in acute myeloid leukaemia. Br. J. Haematol. 135:438-49 (Pubitemid 44583410)
102. Steudel C, Wermke M, Schaich M, Schakel U, Illmer T, et al. 2003. Comparative analysis of MLL partial tandem duplication and FLT3 internal tandem duplication mutations in 956 adult patients with acute myeloid leukemia. Genes Chromosomes Cancer 37:237-51 (Pubitemid 36667562)
103. Whitman SP, Hackanson B, Liyanarachchi S, Liu S, Rush LJ, et al. 2008. DNA hypermethylation and epigenetic silencing of the tumor suppressor gene, SLC5A8, in acute myeloid leukemia with the MLL partial tandem duplication. Blood 112:2013-16
104. Dorrance AM, Liu S, Yuan W, Becknell B, Arnoczky KJ, et al. 2006. Mll partial tandem duplication induces aberrant Hox expression in vivo via specific epigenetic alterations. J. Clin. Investig. 116:2707-16 (Pubitemid 44511634)
105. Frederiksen J, Juul K, Grande P, Jensen GB, Schroeder TV, et al. 2004. Methylenetetrahydrofolate reductase polymorphism (C677T), hyperhomocysteinemia, and risk of ischemic cardiovascular disease and venous thromboembolism: prospective and case-control studies from the Copenhagen City Heart Study. Blood 104:3046-51 (Pubitemid 39507118)
106. Liu HC, Shih LY, May Chen MJ, Wang CC, Yeh TC, et al. 2011. Expression of HOXB genes is significantly different in acute myeloid leukemia with a partial tandem duplication of MLL vs. a MLL translocation: a cross-laboratory study. Cancer Genet. 204:252-59
107. Kocks C, Cho JH, Nehme N, Ulvila J, Pearson AM, et al. 2005. Eater, a transmembrane proteinmediating phagocytosis of bacterial pathogens in Drosophila. Cell 123:335-46 (Pubitemid 41457221)
108. Bach C, Mueller D, Buhl S, Garcia-Cuellar MP, Slany RK. 2009. Alterations of the CxxC domain preclude oncogenic activation of mixed-lineage leukemia 2. Oncogene 28:815-23
109. Wang LM, Ren DM. 2010. Flavopiridol, the first cyclin-dependent kinase inhibitor: recent advances in combination chemotherapy. Mini Rev. Med. Chem. 10:1058-70
110. Rizzolio F, Tuccinardi T, Caligiuri I, Lucchetti C, Giordano A. 2010. CDK inhibitors: from the bench to clinical trials. Curr. Drug Targets 11:279-90
111. Nguyen AT, Taranova O, He J, Zhang Y. 2011. DOT1L, the H3K79 methyltransferase, is required for MLL-AF9-mediated leukemogenesis. Blood 117:6912-22
112. Wang Z, Iwasaki M, Ficara F, Lin C, Matheny C, et al. 2010. GSK-3 promotes conditional association of CREB and its coactivators with MEIS1 to facilitate HOX-mediated transcription and oncogenesis. Cancer Cell 17:597-608
113. Kindler T, Lipka DB, Fischer T. 2010. FLT3 as a therapeutic target in AML: still challenging after all these years. Blood 116:5089-102
114. Wiernik PH. 2010. FLT3 inhibitors for the treatment of acute myeloid leukemia. Clin. Adv. Hematol. Oncol. 8:429-36, 44
115. Chen J, Santillan DA, Koonce M, WeiW, Luo R, et al. 2008. Loss of MLL PHD finger 3 is necessary for MLL-ENL-induced hematopoietic stem cell immortalization. Cancer Res. 68:6199-207
116. Parsons DW, Li M, Zhang X, Jones S, Leary RJ, et al. 2011. The genetic landscape of the childhood cancer medulloblastoma. Science 331:435-39